The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Novartis AG (NYSE:NVS) shares are trading higher in the ... In an interview with CNBC, Novartis CEO Vas Narasimhan downplayed concerns about Entresto’s U.S. patent expiration, which could ...

Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF100.00. According to TipRanks, Welford is a 4-star analyst ...

Proposed Dividend: CHF 3.50 per share, a 6% increase. Novartis AG (NYSE:NVS) reported a strong financial performance for 2024, with a 16% increase in Q4 sales and a 29% rise in core operating ...

CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration, projecting strong growth and margin expansion in 2025. Novartis AG NVS shares are trading higher in the premarket session on ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF109.00. Eric Le Berrigaud has given ...

Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...

The question is: Will the company take it? “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a fourth-quarter earnings call with ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...